Citius Pharmaceuticals Inc (NASDAQ:CTXR) has a beta value of -95.31% and has seen 2.07 shares traded in the last trading session. The company, currently valued at $12.07M, closed the last trade at $0.91 per share which meant it lost -$4.09 on the day or 1.08% during that session. The CTXR stock price is -2784.62% off its 52-week high price of $26.25 and 28.57% above the 52-week low of $0.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 11.68 million shares traded. The 3-month trading volume is 1.40 shares.
The consensus among analysts is that Citius Pharmaceuticals Inc (CTXR) is Buy stock at the moment, with a recommendation rating of 58.09. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Sporting 1.08% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CTXR stock price touched $0.91 or saw a rise of 26.61%. Year-to-date, Citius Pharmaceuticals Inc shares have moved -92.99%, while the 5-day performance has seen it change 17.39%. Over the past 30 days, the shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) have changed 46.22%. Short interest in the company has seen 0.66 million shares shorted with days to cover at 4.54.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
The company’s shares have lost -58.14% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.93% 20.90% over the past 5 years.
CTXR Dividends
Citius Pharmaceuticals Inc is expected to release its next earnings report on 2025-May-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Insiders own 4.41% of the company shares, while shares held by institutions stand at 5.74% with a share float percentage of 6.01%. Investors are also buoyed by the number of investors in a company, with Citius Pharmaceuticals Inc having a total of 34.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 10.16 million shares worth more than $5.93 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 6.3845% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.69 million and represent 3.9776% of shares outstanding.
